BioWorld Asia

July 12, 2006

Intercell's €110M Funding Provides Exit Opportunity

Intercell AG rounded off the largest fund raising in Europe this year, with the placing of an overallotment of 1.3 million shares, bringing the total to €110.6 million (US$140.9 million). (BioWorld International) Read More

Genmab's Humax-CD20 Starts Phase III Work With NHL Focus

Breast Cancer Gene Might Mean Help For More Women

Novozymes Getting Protein Production, More From Delta

Early Funding Source To Be Provided By IP Group

Eurofins Scientific Invests In Danish, Japanese Food Firms

LTKfarma Setting Up Shop With Product In Phase I/II

Paradigm's Fourth Round: £7M For Cancer Drug Trials

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

Amlogenyx’s AM-805 reduces amyloid plaques in AD

BioWorld Science

The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026